IPO Journey
XORTX Therapeutics Inc.
IPO Date: May 15, 2026 · 3 filings tracked
Final Offer Terms
Ticker
XRTX
Exchange
Nasdaq Capital Market
Offer Price
$1.88
Shares Offered
183,577
Estimated Proceeds
$345.1K
Underwriters
Led by E.F. Hutton & Co.
Filing Timeline
1
F-1
September 25, 2025
- Clinical-stage biotech focused on high-potential uric acid treatment
- Lead program XORLO™ targeting a $700 million annual gout market
2
F-1/A
February 13, 2026
- Clinical-stage biotech focused on high-growth kidney and heart disease markets
- Proprietary XORLO™ drug delivery technology designed to improve existing medicine efficacy
Changes from previous filing
- ▸ Final offer price: $0.4 per share
- ▸ Shares offered: 12,500,000
- ▸ Estimated proceeds: $5M
424B4
Final Pricing
May 15, 2026
- Clinical-stage focus on high-demand kidney health and purine metabolism
- Pipeline-in-a-product strategy leveraging lead drug XORLO for multiple indications
Changes from previous filing
- ▸ Final offer price: $1.88 per share
- ▸ Shares offered: 183,577
- ▸ Estimated proceeds: $0M
- ▸ Underwriters: E.F. Hutton & Co.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.